Emmanuel Zuber

Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology

Werner Brannath, Emmanuel Zuber, Michael Branson et al. · Statistics in Medicine · 2009 · 190 citations

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

Carmelo Pozzo, C. Barone, J. Szántó et al. · Annals of Oncology · 2004 · 157 citations · Full text

Oncology, Esophageal Cancer, Esophageal-gastric Junction Adenocarcinoma +8

51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325)

E. Van Cutsem, Vladimir Moiseyenko, S. Tjulandin et al. · European Journal of Cancer Supplements · 2003 · 90 citations

Gastrointestinal Oncology, Medicine, Metronomic Therapy +9

Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials

Mouna Akacha, Janice Branson, Frank Bretz et al. · Statistics in Biopharmaceutical Research · 2020 · 44 citations · Full text

Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma

Pasi Korhonen, Emmanuel Zuber, Michael Branson et al. · Journal of Biopharmaceutical Statistics · 2012 · 35 citations